Table 2.
Characteristics of the dogs included in the study and their responses to imatinib mesylate (IM) or vinblastine and prednisone (VP).
| Dog | Sex | Age (Years) |
Breed | Metastasis | Target Tumor |
WHO Stage * |
Grade (Patnaik/ Kiupel) |
KIT Staining Pattern ** | % Variation of the Longest Diameter (Target Lesion) | Response According to VCOG *** |
| Imatinib Mesylate (IM) | ||||||||||
| C5IM | M | 7 | Boxer | Absent | Genital /perianal | IIIa | 2/Low | 2 | 13 | SD |
| C6IM | M | 8 | Mongrel | Absent | LHL | Ia | 2/Low | 2 | 21.1 | PD |
| C11IM | F | 12 | Siberian Husky | Absent | Head/Neck | IIIb | 2/Low | 2 | 23.3 | PD |
| C12IM | F | 8 | Labrador | Absent | RHL | Ia | 2/Low | 2 | −43.2 | PR |
| C14IM | M | 2 | Bulldog | Absent | RHL | Ia | 2/Low | 2 | 7.5 | SD |
| C15IM | F | 10 | Boxer | Mandibula lymph node | Head/Neck | IIIb | 2/Low | 3 | −100 | CR |
| C17IM | F | 5 | Bernese | Cervical lymph node | RHL | IIa | 2/Low | 3 | −40.8 | PR |
| C22IM | M | 9 | Yorkshire Terrier | Inguinal lymph node | Genital/perianal | IIIa | 2/Low | 1 | 77.7 | PD |
| C25IM | F | 6 | Mongrel | Absent | Trunk | IIIa | 2/Low | 2 | −15.3 | SD |
| C27IM | F | 16 | Mongrel | Cervical lymph node | LFL | IIIb | 2/Low | 3 | 33.07 | PD |
| C28IM | F | 13 | Mongrel | Absent | Trunk | IIIb | 2/Low | 3 | −16.8 | SD |
| C29IM | M | 8 | Yorkshire Terrier | Absent | LHL | Ia | 2/Low | 2 | −55.9 | PR |
| C30IM | M | 8 | Mongrel | Absent | LHL | Ia | 2/Low | 2 | −4.39 | SD |
| Vinblastine and Prednisone (VP) | ||||||||||
| C4VP | M | 7 | Mongrel | Absent | Trunk | Ia | 2/Low | 3 | 0.2 | SD |
| C7VP | F | 10 | Mongrel | Absent | RHL | IIIa | 2/Low | 2 | 30.9 | PD |
| C8VP | F | 10 | Rotweiler | Absent | RHL | IIIa | 2/Low | 2 | 20.7 | PD |
| C9VP | M | 10 | Golden Retriever | Absent | Genital/perianal | IIIa | 2/Low | 2 | −22.7 | SD |
| C10VP | M | 4 | Boxer | Absent | Trunk | Ia | 2/Low | 3 | −14.9 | SD |
| C16VP | F | 9 | Pit bull | Absent | Trunk | IIIa | 2/Low | 2-3 | −15.1 | SD |
| C19VP | F | 5 | Golden Retriever | Absent | Head/Neck | Ia | 2/Low | 2 | 14.7 | SD |
| C21VP | F | 6 | Boxer | Absent | LHL | Ia | 2/Low | 1 | −13.8 | SD |
| C23VP | M | 8 | Labrador | Inguinal lymph node | Genital/perianal | IIb | 3/High | 2 | 43.9 | PD |
| C24VP | M | 9 | Labrador | Satellite lesions | Trunk | IIIa | 2/Low | 2 | 27.2 | PD |
| C26VP | M | 7 | Dogo Argentino | Popliteal lymph node | LHL | IIIa | 2/Low | 3 | −42.1 | PR |
LHL = left hind limb; RHL = right hind limb; LFL = left fore limb. * WHO Staging system—Owen, 1980 [25]. ** Classification of the staining pattern was done according to: (1) Membrane-associated staining, (2) Focal to stippled cytoplasmic staining with decreased membrane-associated staining; and (3) diffuse cytoplasmic staining. *** CR = complete response, PR = partial response, SD = stable disease, and PD = progressive disease.